

Mandatory Unconditional Cash Offer

by

ABN AMRO Bank N.V., Singapore Branch

(Incorporated in the Netherlands)

for and on behalf of

LuYe Pharmaceutical Investment Co., Ltd

(Company Registration No: 200942)

(Incorporated in the Cayman Islands)

to acquire all the issued and paid-up ordinary shares in the capital of

AsiaPharm Group Ltd

(Company Registration No: 33854)

(Incorporated in Bermuda)

1. INTRODUCTION

ABN AMRO Bank N.V., Singapore Branch (“**ABN AMRO**”) refers to the offer document dated 22 February 2008 (the “**Offer Document**”) and the announcement dated 25 March 2008 in connection with the mandatory unconditional cash offer by ABN AMRO, for and on behalf of LuYe Pharmaceutical Investment Co., Ltd (the “**Offeror**”), for all the issued and paid-up ordinary shares of US\$0.02 (“**Shares**”) in the capital of AsiaPharm Group Ltd (“**AsiaPharm**” or the “**Company**”).

All capitalised terms used and not defined herein shall have the same meanings given to them in the Offer Document.

2. EXTENSION OF CLOSING DATE

ABN AMRO wishes to announce, for and on behalf of the Offeror, that the Closing Date of the Offer will be extended from 5.30 p.m. on Tuesday, 22 April 2008 to 5.30 p.m. on Tuesday, 29 April 2008 or such later date(s) as may be announced from time to time by or on behalf of the Offeror.

Accordingly, the Offer shall close at 5.30 p.m. on Tuesday, 29 April 2008 or such later date(s) as may be announced from time to time by or on behalf of the Offeror.

3. RESPONSIBILITY STATEMENT

The director of the Offeror, Mr Kuo-Chuan Kung, and Mr Liu Dianbo (who may each have delegated detailed supervision of this announcement) have taken all reasonable care to ensure that the facts stated and all opinions expressed in this announcement are fair and accurate and that no material facts have been omitted from this announcement, and they jointly and severally accept responsibility accordingly. Where any information has been extracted or reproduced from published or otherwise publicly available sources (including, without limitation, in relation to the Company or its subsidiaries), the sole responsibility of the

director of the Offeror, Mr Kuo-Chuan Kung and Mr Liu Dianbo has been to ensure, through reasonable enquires, that such information is accurately extracted from such sources or, as the case may be, reflected or reproduced in this announcement.

Issued by

ABN AMRO Bank N.V., Singapore Branch

For and on behalf of

LuYe Pharmaceutical Investment Co., Ltd

22 April 2008

Singapore